Medications for Renal Cell Carcinoma

14 results

  • Afinitor

    (everolimus)
    Novartis Pharmaceuticals Corporation
    Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

  • Depo-provera (medroxyprogesterone acetate)

    (medroxyprogesterone acetate)
    Physicians Total Care, Inc.
    Usage: This drug is indicated for use as adjunctive therapy and for palliative treatment in cases of inoperable, recurrent, and metastatic endometrial or renal carcinoma.

  • Everolimus (everolimus)

    (Everolimus)
    Natco Pharma Limited
    Usage: Everolimus is indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, and for adult patients with progressive neuroendocrine tumors, renal cell carcinoma post sunitinib/sorafenib failure, renal angiomyolipoma in tuberous sclerosis, and subependymal giant cell astrocytoma in TSC.

  • Fotivda

    (Tivozanib)
    AVEO Pharmaceuticals, Inc.
    Usage: FOTIVDA is indicated for treating adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic therapies.

  • Inlyta (axitinib)

    (axitinib)
    U.S. Pharmaceuticals
    Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.

  • Keytruda

    (pembrolizumab)
    Merck Sharp & Dohme LLC
    Usage: KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma, among others. It is utilized in different settings, such as first-line treatment, adjuvant therapy, and for those with advanced or refractory disease.

  • Pazopanib (pazopanib hydrochloride)

    (pazopanib hydrochloride)
    Novugen Pharma (USA) LLC.
    Usage: Pazopanib tablets are indicated for adults with advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Efficacy for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.

  • Pazopanib (pazopanib)

    (Pazopanib)
    SUN PHARMACEUTICAL INDUSTRIES, INC.
    Usage: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors.

  • Sorafenib (sorafenib)

    (Sorafenib)
    Teva Pharmaceuticals Inc
    Usage: Sorafenib tablets are indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

  • Sutent

    (Sunitinib malate)
    Pfizer Laboratories Div Pfizer Inc
    Usage: SUTENT is indicated for adult patients with gastrointestinal stromal tumors (GIST) after imatinib failure, advanced renal cell carcinoma (RCC), adjuvant treatment in high-risk recurrent RCC post-nephrectomy, and progressive well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable locally advanced or metastatic cases.